The dose-reponse effects of the additional Auger and IC electrons of 161Tb- compared to 177Lu- labelled agonists and antagonists

Kaat Spoormans; Lara Struelens; Koen Vermeulen; Marijke De Saint-Hubert; Michel Koole; Melissa Crabbé

The dose-reponse effects of the additional Auger and IC electrons of 161Tb- compared to 177Lu- labelled agonists and antagonists

Kaat Spoormans, Lara Struelens, Koen Vermeulen, Marijke De Saint-Hubert, Michel Koole, Melissa Crabbé

TRT-Radiopharmaceuticals

Research output › peer-review

3 Downloads (Pure)

Abstract

Preclinical data have shown that 161Tblabelled peptides targeting the somatostatin receptor (SSTR) are therapeutically more effective for peptide receptor radionuclide therapy (PRRT) compared to their 177Lu-labelled counterparts. To further substantiate this enhanced therapeutic effect, we
performed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness (RBE) in vitro.

Original language	English
Title of host publication	EANM’24 Abstract Book
Publisher	EANM - European Association of Nuclear Medicine
Chapter	205
Number of pages	1
Edition	2024
State	Published - 2024

Access to Document

s00259-024-06838-zFinal published version, 21.4 MBLicense: Unspecified

Cite this

@inproceedings{62fdb183892c448590c412eabd0439a4,

title = "The dose-reponse effects of the additional Auger and IC electrons of 161Tb- compared to 177Lu- labelled agonists and antagonists",

abstract = "Preclinical data have shown that 161Tblabelled peptides targeting the somatostatin receptor (SSTR) are therapeutically more effective for peptide receptor radionuclide therapy (PRRT) compared to their 177Lu-labelled counterparts. To further substantiate this enhanced therapeutic effect, weperformed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness (RBE) in vitro.",

keywords = "177Lu-DOTATATE, 161Tb-DOTATATE, Peptide receptor radionuclide therapy, PRRT",

author = "Kaat Spoormans and Lara Struelens and Koen Vermeulen and {De Saint-Hubert}, Marijke and Michel Koole and Melissa Crabb{\'e}",

note = "Score=3",

year = "2024",

language = "English",

booktitle = "EANM{\textquoteright}24 Abstract Book",

publisher = "EANM - European Association of Nuclear Medicine",

address = "Austria",

edition = "2024",

}

TY - GEN

T1 - The dose-reponse effects of the additional Auger and IC electrons of 161Tb- compared to 177Lu- labelled agonists and antagonists

AU - Spoormans, Kaat

AU - Struelens, Lara

AU - Vermeulen, Koen

AU - De Saint-Hubert, Marijke

AU - Koole, Michel

AU - Crabbé, Melissa

N1 - Score=3

PY - 2024

Y1 - 2024

N2 - Preclinical data have shown that 161Tblabelled peptides targeting the somatostatin receptor (SSTR) are therapeutically more effective for peptide receptor radionuclide therapy (PRRT) compared to their 177Lu-labelled counterparts. To further substantiate this enhanced therapeutic effect, weperformed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness (RBE) in vitro.

AB - Preclinical data have shown that 161Tblabelled peptides targeting the somatostatin receptor (SSTR) are therapeutically more effective for peptide receptor radionuclide therapy (PRRT) compared to their 177Lu-labelled counterparts. To further substantiate this enhanced therapeutic effect, weperformed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness (RBE) in vitro.

KW - 177Lu-DOTATATE

KW - 161Tb-DOTATATE

KW - Peptide receptor radionuclide therapy

KW - PRRT

M3 - In-proceedings paper

BT - EANM’24 Abstract Book

PB - EANM - European Association of Nuclear Medicine

ER -